Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials
暂无分享,去创建一个
M. Jorge Cardoso | Nick C Fox | Kate E. Macdonald | M. Modat | S. Ourselin | C. Rowe | J. Schott | J. Barnes | K. Leung | V. Villemagne | K. Andrews | Tom Yeatman | T. Yeatman
[1] Alexander Hammers,et al. Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe , 2003, Human brain mapping.
[2] W. M. van der Flier,et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.
[3] J. H. Ward. Hierarchical Grouping to Optimize an Objective Function , 1963 .
[4] Sébastien Ourselin,et al. Brain MAPS: An automated, accurate and robust brain extraction technique using a template library , 2011, NeuroImage.
[5] C. Jack,et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer’s disease , 2010, Brain : a journal of neurology.
[6] C. Jack,et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.
[7] Paul M. Thompson,et al. Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils , 2008, NeuroImage.
[8] Sébastien Ourselin,et al. STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation , 2013, Medical Image Anal..
[9] Nick C Fox,et al. Volume changes in Alzheimer’s disease and mild cognitive impairment: cognitive associations , 2010, European Radiology.
[10] Norbert Schuff,et al. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease , 2010, NeuroImage.
[11] Emma B. Lewis,et al. Correction of differential intensity inhomogeneity in longitudinal MR images , 2004, NeuroImage.
[12] Sébastien Ourselin,et al. Fast free-form deformation using graphics processing units , 2010, Comput. Methods Programs Biomed..
[13] C. Rowe,et al. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition , 2012, Neurology.
[14] Nick C Fox,et al. Combining short interval MRI in Alzheimer’s disease , 2006, Journal of Neurology.
[15] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[16] Paul Maruff,et al. β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .
[17] Sébastien Ourselin,et al. Reconstructing a 3D structure from serial histological sections , 2001, Image Vis. Comput..
[18] Jeffrey A. James,et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.
[19] Denise C. Park,et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.
[20] Marc Modat,et al. LoAd: A locally adaptive cortical segmentation algorithm , 2011, NeuroImage.
[21] Norbert Schuff,et al. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. , 2011, Brain : a journal of neurology.
[22] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[23] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[24] Kewei Chen,et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.
[25] C. Rowe,et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease , 2009, International Psychogeriatrics.
[26] Nick C Fox,et al. Imaging cerebral atrophy: normal ageing to Alzheimer's disease , 2004, The Lancet.
[27] J. Barnes,et al. A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus , 2008, NeuroImage.
[28] J. Gunter,et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.
[29] J. Trojanowski,et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.
[30] Chengjie Xiong,et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.
[31] C. Rowe,et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2010, Neurobiology of Aging.
[32] Abraham Z. Snyder,et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume , 2004, NeuroImage.
[33] Nick C Fox,et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.
[34] Michael Weiner,et al. Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection , 2010, NeuroImage.
[35] Olivier Salvado,et al. Larger temporal volume in elderly with high versus low beta-amyloid deposition. , 2010, Brain : a journal of neurology.
[36] Nick C Fox,et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease , 2009, Neurology.
[37] Karl Herholz,et al. Clinical amyloid imaging in Alzheimer's disease , 2011, The Lancet Neurology.
[38] A. Fagan,et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.
[39] L. Schneider,et al. Prevention trials in Alzheimer's disease: An EU-US task force report , 2011, Progress in Neurobiology.
[40] Nick C Fox,et al. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42 , 2010, Annals of neurology.
[41] S Ourselin,et al. β-Amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia , 2010, Neurology.
[42] A. Fagan,et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging , 2010, Annals of neurology.
[43] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[44] A. Hebrank,et al. β-Amyloid burden in healthy aging , 2012, Neurology.
[45] Denise C. Park,et al. &bgr;-Amyloid burden in healthy aging: Regional distribution and cognitive consequences , 2012, Neurology.
[46] Nick C Fox,et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. , 1996, Brain : a journal of neurology.
[47] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[48] Nick C Fox,et al. Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment , 2010, Neurobiology of Aging.